{"id":"W4249931646","doi":"10.1200/jco.2019.37.7_suppl.171","title":"Keynote-365 cohort C: Pembrolizumab (pembro) plus enzalutamide (enza) in abiraterone (abi)-pretreated patients (pts) with metastatic castrate resistant prostate cancer (mCRPC).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; Western University","funders":"","keywords":"Medicine; Enzalutamide; Abiraterone; Nausea; Prostate cancer; Pembrolizumab; Cancer; Cohort; Internal medicine; Oncology; Gynecology; Immunotherapy; Androgen receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009666921,0.0008515559,0.0007208748,0.0003006095,0.0005891476,0.0007207931,0.0007074947,0.0007854166,0.006834854],"category_scores_gemma":[0.0007201199,0.0002853487,0.001169326,0.0004711692,0.0004060701,0.0004708037,0.0005304625,0.001533072,0.001252719],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001714066,"about_ca_system_score_gemma":0.00281323,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.005914612,"about_ca_topic_score_gemma":0.008091035,"domain_scores_codex":[0.9995988,0.0001069341,0.00004194417,0.00008773102,0.00005867305,0.000105997],"domain_scores_gemma":[0.9992862,0.00006129164,0.0001428463,0.00007959439,0.000071854,0.0003582433],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7372105,0.03236668,0.08646001,0.001282957,0.002185106,0.0008623428,0.0004438038,0.003365119,0.02211173,0.0004844165,0.01843414,0.0947932],"study_design_scores_gemma":[0.3128404,0.4350358,0.1952573,0.0002849305,0.002118558,0.001989205,0.0003706057,0.001550344,0.009579292,0.0004306213,0.04045844,0.00008446845],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9734407,0.001685962,0.0005069326,0.0003028979,0.00008246912,0.00566809,0.01398468,0.00005224956,0.004275982],"genre_scores_gemma":[0.9650763,0.001213853,0.001661731,0.001088729,0.0001802477,0.003705438,0.02237973,0.00002440183,0.004669486],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006834854,"threshold_uncertainty_score":0.02286488,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07638448730761598,"score_gpt":0.439758731083495,"score_spread":0.363374243775879,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}